Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers.
作者信息
Ter Chao Chia
出版信息
Clinics (Sao Paulo). 2011;66(7):1275-6. doi: 10.1590/s1807-59322011000700025.
Abstract
摘要
相似文献
1
Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers.
Clinics (Sao Paulo). 2011;66(7):1275-6. doi: 10.1590/s1807-59322011000700025.
2
Predictors of low cardiac output in decompensated severe heart failure.
Clinics (Sao Paulo). 2011;66(2):239-44. doi: 10.1590/s1807-59322011000200010.
3
Left ventricular ejection fraction in addition to N-terminal pro-B-type natriuretic peptide for risk stratification in the ambulant elderly: get the picture...or not?
J Am Coll Cardiol. 2011 Sep 27;58(14):1507-8. doi: 10.1016/j.jacc.2011.06.039.
4
Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.
Circ Heart Fail. 2011 Sep;4(5):538-40. doi: 10.1161/CIRCHEARTFAILURE.111.963710.
5
B-type natriuretic peptide levels in heart failure patients with preserved and reduced ejection fraction.
J Am Coll Cardiol. 2013 Aug 6;62(6):567. doi: 10.1016/j.jacc.2013.04.053. Epub 2013 May 20.
6
Natriuretic peptides, ejection fraction, and prognosis: parsing the phenotypes of heart failure.
J Am Coll Cardiol. 2013 Apr 9;61(14):1507-9. doi: 10.1016/j.jacc.2013.01.039.
7
Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure.
Eur J Heart Fail. 2007 Jun-Jul;9(6-7):667-73. doi: 10.1016/j.ejheart.2007.01.003. Epub 2007 Mar 23.
8
[Device therapy in chronic heart failure].
Ther Umsch. 2011 Feb;68(2):89-93. doi: 10.1024/0040-5930/a000125.
9
ST2 and B-type natriuretic peptide kinetics during exercise in severe heart failure.
Eur J Heart Fail. 2018 Oct;20(10):1494-1495. doi: 10.1002/ejhf.1246. Epub 2018 Jul 27.
10
Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry.
Clin Res Cardiol. 2021 Sep;110(9):1392-1403. doi: 10.1007/s00392-020-01689-8. Epub 2020 Jun 25.
本文引用的文献
1
Predictors of low cardiac output in decompensated severe heart failure.
Clinics (Sao Paulo). 2011;66(2):239-44. doi: 10.1590/s1807-59322011000200010.
2
Use of digoxin for heart failure and atrial fibrillation in elderly patients.
Am J Geriatr Pharmacother. 2010 Oct;8(5):419-27. doi: 10.1016/j.amjopharm.2010.10.001.
3
Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure.
Rev Soc Bras Med Trop. 2010 Sep-Oct;43(5):496-9. doi: 10.1590/s0037-86822010000500004.
4
Treatment of systolic heart failure in the elderly: an evidence-based review.
Ann Pharmacother. 2010 Oct;44(10):1604-14. doi: 10.1345/aph.1P128. Epub 2010 Sep 14.
5
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.
Eur Heart J. 2006 Jan;27(2):178-86. doi: 10.1093/eurheartj/ehi687. Epub 2005 Dec 8.
6
Association of serum digoxin concentration and outcomes in patients with heart failure.
JAMA. 2003 Feb 19;289(7):871-8. doi: 10.1001/jama.289.7.871.
7
Renal blood flow autoregulation in blood pressure control.
Curr Opin Nephrol Hypertens. 2002 Jan;11(1):67-72. doi: 10.1097/00041552-200201000-00010.
8
Detection of apical Na(+)/H(+) exchanger activity inhibition in proximal tubules induced by acute hypertension.
Am J Physiol Regul Integr Comp Physiol. 2000 Oct;279(4):R1412-8. doi: 10.1152/ajpregu.2000.279.4.R1412.
9
Blood pressure variability and urine flow in the conscious dog.
Am J Physiol. 1998 Apr;274(4):F680-6. doi: 10.1152/ajprenal.1998.274.4.F680.
10
The effect of digoxin on mortality and morbidity in patients with heart failure.
N Engl J Med. 1997 Feb 20;336(8):525-33. doi: 10.1056/NEJM199702203360801.
Zotero 插件